S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Kinnate Biopharma Stock Forecast, Price & News

+0.40 (+1.06 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $37.97
50-Day Range
MA: $39.31
52-Week Range
Now: $37.97
Volume54,521 shs
Average Volume138,448 shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company's lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. Kinnate Biopharma Inc. was founded in 2018 and is headquartered in San Diego, California.


Overall MarketRank

2.03 out of 5 stars

Medical Sector

45th out of 1,926 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:KNTE
Phone858 299 4699



Sales & Book Value

Annual SalesN/A



Market Cap$1.58 billion
Next Earnings DateN/A
OptionableNot Optionable
+0.40 (+1.06 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KNTE News and Ratings via Email

Sign-up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kinnate Biopharma (NASDAQ:KNTE) Frequently Asked Questions

Is Kinnate Biopharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kinnate Biopharma stock.
View analyst ratings for Kinnate Biopharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Kinnate Biopharma?

Wall Street analysts have given Kinnate Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kinnate Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Kinnate Biopharma's CEO?

1,448 employees have rated Kinnate Biopharma CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Kinnate Biopharma's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What price target have analysts set for KNTE?

4 equities research analysts have issued 12-month price objectives for Kinnate Biopharma's shares. Their forecasts range from $48.00 to $60.00. On average, they anticipate Kinnate Biopharma's share price to reach $52.00 in the next year. This suggests a possible upside of 37.0% from the stock's current price.
View analysts' price targets for Kinnate Biopharma
or view Wall Street analyst' top-rated stocks.

Who are some of Kinnate Biopharma's key competitors?

Who are Kinnate Biopharma's key executives?

Kinnate Biopharma's management team includes the following people:
  • Dr. Eric Anthony Murphy Ph.D., Chief Scientific Officer (Age 46, Pay $403.77k)
  • Mr. Nima Farzan, Pres, CEO & Director (Age 45)
  • Mr. Mark A. Meltz, COO, Gen. Counsel, Treasurer & Sec. (Age 48)
  • Dr. Richard Thomas Williams MBBS, Ph.D., Chief Medical Officer (Age 53)
  • Dr. Robert Kania Ph.D., Sr. VP of Drug Discovery
  • Mr. Eric Martin Ph.D., Sr. VP of Translational Medicine

When did Kinnate Biopharma IPO?

(KNTE) raised $170 million in an initial public offering (IPO) on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.

What is Kinnate Biopharma's stock symbol?

Kinnate Biopharma trades on the NASDAQ under the ticker symbol "KNTE."

When did the company's quiet period expire?

Kinnate Biopharma's quiet period expired on Tuesday, January 12th. Kinnate Biopharma had issued 12,000,000 shares in its public offering on December 3rd. The total size of the offering was $240,000,000 based on an initial share price of $20.00. During the company's quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Kinnate Biopharma?

Shares of KNTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kinnate Biopharma's stock price today?

One share of KNTE stock can currently be purchased for approximately $37.97.

How big of a company is Kinnate Biopharma?

Kinnate Biopharma has a market capitalization of $1.58 billion.

What is Kinnate Biopharma's official website?

The official website for Kinnate Biopharma is www.kinnate.com.

How can I contact Kinnate Biopharma?

The company can be reached via phone at 858 299 4699.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.